Recent Updates in the Role of Bispecifics in Multiple Myeloma: Highlights from ASH 2022 and Beyond

home / readout-360 / recent-updates-in-the-role-of-bispecifics-in-multiple-myeloma-highlights-from-ash-2022-and

Shaji Kumar, MD, Sandy Wong, MD, and Alexander Lesokhin, MD, review key data updates on the use of bispecific antibodies for the treatment of multiple myeloma presented at ASH 2022 and other recent meetings, and discuss how recent clinical trials have influenced treatment approaches in both the transplant-eligible and -ineligible patient populations.